At the Johns Hopkins School of Medicine Division of Rheumatology, Baltimore, registered nurses (RNs) are an integral aspect of the rheumatology fellowship program. This gives the fellows information and insight into areas of practice they might not otherwise receive. “This [practice] is a result of our very strong belief that an integrated and interdisciplinary approach,…
COVID-19 Poses Training Challenges for Rheumatology Fellows
Like the medical profession itself, the education of doctors serving in rheumatology fellowships across the nation marches on despite the unexpected hurdles posed by the COVID-19 pandemic. Practice Changes “The pandemic has changed the way our fellows see patients; we are now seeing almost all patients using telemedicine,” says Bonita Libman, MD, FACR, FACP, fellowship…
25 Guiding Principles for Rheumatology Trainees
As rheumatologists, we relish the thrill of diagnostic conundrums that accompany our immune-mediated multi-system and often undifferentiated disease processes. Many rheumatologic diagnoses are essentially diagnoses of exclusion. We’re accustomed to diagnosing iatrogenesis, infection and malignancy as often as we diagnose rheumatic disease. Complex clinical problem solving and critical reasoning are our forte, and to do…
Ultrasound in Rheumatology—Past, Present & Future
For most rheumatologists, the key elements of the physical exam—inspection, palpation, percussion and auscultation—have long been second nature, but a fifth modality has grown in importance with respect to making the correct diagnosis: ultrasound. From evaluating for Doppler signal and additional findings indicative of synovitis to identifying bony erosions, chondrocalcinosis, tophi and other articular and…
5 Takeaways from the 2018 Rheumatology Fellowship Match Data
If you’re a rheumatologist, you likely remember the moment of truth on your match day—the day of revelation, when the complex computer algorithm set up by the National Resident Matching Program (NRMP) accommodates the wishes of programs and applicants and then discloses into which program an applicant has been placed. Although it has always been…
A Call to Action to Use the Pandemic to Transform Rheumatic Disease Care
No event in recent history has caused such far-reaching changes within the medical industry as the ongoing COVID-19 pandemic. Similar to its ability to spread indiscriminately—infecting people regardless of age, race or socioeconomic background—the virus is inducing immediate and, likely, permanent changes across the entire spectrum of healthcare. Comfortable routines of healthcare delivery have been…
The ACR Is Helping Rheumatology Practices Meet COVID-19 Challenges
These are difficult times for rheumatologists. We have seen sharp declines in face-to-face patient visits since the COVID‑19 pandemic began. Many of us have questions about the best ways to maintain employee and patient safety while keeping our practices afloat and continuing to provide optimal care. The volunteer leaders at the ACR continue to care…
The Half-Life of the Truth
My fellow was laughing at me. By itself, I don’t think this was an unusual occurrence. I am quite certain that my fellows laugh at me all the time. That said, when such laughter is called for, I am accustomed to a certain protocol being observed. In general, I expect the laughter to be contained,…
How Duke’s School of Medicine Implemented a Quality Improvement Curriculum
It has been about 20 years since the Institute of Medicine (now the National Academy of Medicine) published the report To Err Is Human: Building a Safer Health System, shining light on the impact of medical errors in healthcare.1 In response to that publication, the focus on quality improvement (QI) started in the inpatient setting,…
FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis
HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…
- « Previous Page
- 1
- …
- 175
- 176
- 177
- 178
- 179
- …
- 800
- Next Page »